Holen Sie sich die Stockscreener-App
13.39
3.46%
0.448
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews
Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan
Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily
INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI
MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MiNK Therapeutics, Inc. (INKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - geneonline.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - Investing News Network
HC Wainwright Issues Positive Outlook for INKT Earnings - MarketBeat
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - Sahm
MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026 - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ... - Caledonian Record
MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Cancer and ARDS data from MiNK's cell therapy heads to ASGCT - Stock Titan
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society 2026 International Conference - Investing News Network
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
MiNK Therapeutics Announces Abstract Acceptance for - GlobeNewswire
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - Investing News Network
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2025 Earnings Conference - Moomoo
MiNK Therapeutics (NASDAQ: INKT) expands iNKT trials as losses grow and going-concern risk flagged - Stock Titan
MiNK Therapeutics 2025 10-K: Net loss $(2.93) per share, $12.49M net loss - TradingView
MiNK Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
MiNK Therapeutics Reports 2025 Results and Advances Phase 2 iNKT Cell Therapy Programs for ARDS, GVHD, and Oncology - Minichart
MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
INKT: Durable clinical results, strong cash position, and major trial milestones expected in 2026 - TradingView — Track All Markets
Earnings call transcript: MiNK Therapeutics’ Q4 2025 shows cash boost amid wider losses - Investing.com India
MiNK Therapeutics Q4 Earnings Call Highlights - MarketBeat
MiNK Therapeutics (NASDAQ: INKT) details 2025 loss and cash runway into 2026 - Stock Titan
MiNK Therapeutics Initiates Phase 2 Trials for ARDS and GVHD, Planning Multiple Clinical Catalysts for 2026 - Quiver Quantitative
Ideas Watch: What is the target price for MiNK Therapeutics Inc stockWeekly Trade Report & Reliable Trade Execution Plans - baoquankhu1.vn
Whale Trades: Whats the fair value of MiNK Therapeutics Inc stock2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
MiNK Therapeutics pediatric cancer breakthrough sparks stock rally - MSN
Activity Recap: Is MiNK Therapeutics Inc stock heavily shorted2026 Rallies & Low Risk Growth Stock Ideas - baoquankhu1.vn
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight ... - Caledonian Record
MiNK Therapeutics clarifies status of agenT-797 combination trial discussions By Investing.com - Investing.com Australia
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations - TipRanks
Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments - TradingView
MiNK Therapeutics clarifies status of agenT-797 combination trial discussions - Investing.com
1.76%
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):